Precision medicine as an approach to autoimmune diseases

Abstract Autoimmune disease, which are quite common, are complex and heterogeneous conditions that can be difficult to diagnose, treat and manage. Consequently, this group of disease generates a major burden on global health care systems. Despite significant efforts and advances in the field of autoimmunity, challenges persist that require a more precise approach to potentially leveraging big data composed of demographic, clinical and biomarker data combined with augmented intelligence. This book chapter provides a high-level overview of some of the challenges in autoimmunity and elaborates on progress to date.

[1]  E. Katchalski‐Katzir,et al.  Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Fritzler,et al.  Autoantibodies in SLE: prediction and the p value matrix , 2019, Lupus.

[3]  M. Petri,et al.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[4]  K. Deane,et al.  Rheumatoid Arthritis Prevention: Challenges and Opportunities to Change the Paradigm of Disease Management. , 2019, Clinical therapeutics.

[5]  R. Cervera,et al.  Moving towards a molecular taxonomy of autoimmune rheumatic diseases , 2018, Nature Reviews Rheumatology.

[6]  Mary F. Wisniewski,et al.  Diagnostic error in medicine: analysis of 583 physician-reported errors. , 2009, Archives of internal medicine.

[7]  V. Holers,et al.  The Natural History of Rheumatoid Arthritis. , 2019, Clinical therapeutics.

[8]  U. Schneider,et al.  Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies , 2019, Front. Neurol..

[9]  M. Fritzler,et al.  Redefining systemic lupus erythematosus — SMAARTT proteomics , 2018, Nature Reviews Rheumatology.

[10]  M. Alarcón‐Riquelme,et al.  Moving towards a molecular taxonomy of autoimmune rheumatic diseases , 2018, Nature Reviews Rheumatology.

[11]  The Inaccuracy of Ocular Online Symptom Checkers-Googlers Beware. , 2019, JAMA ophthalmology.

[12]  V. Holers,et al.  Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis , 2019, Arthritis & Rheumatology.

[13]  M. Mahler Population-based screening for ACPAs: a step in the pathway to the prevention of rheumatoid arthritis? , 2017, Annals of the rheumatic diseases.

[14]  S. Antinori,et al.  COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? , 2020, Clinical and experimental rheumatology.

[15]  M. Panagopoulou,et al.  Are the Origins of Precision Medicine Found in the Corpus Hippocraticum? , 2017, Molecular Diagnosis & Therapy.

[16]  P. Tak,et al.  Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials , 2012, Annals of the rheumatic diseases.

[17]  Y. Shoenfeld,et al.  Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity , 2006, Lupus.

[18]  Jessilyn Dunn,et al.  Windows Into Human Health Through Wearables Data Analytics. , 2019, Current opinion in biomedical engineering.

[19]  F. Chiarelli,et al.  Prediction and prevention of type 1 diabetes in children , 2019, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

[20]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[21]  M. Gariboldi,et al.  Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review , 2019, Journal of Endocrinological Investigation.

[22]  Hangwi Tang,et al.  Googling for a diagnosis—use of Google as a diagnostic aid: internet based study , 2006, BMJ : British Medical Journal.

[23]  X. Mariette,et al.  The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy , 2017, Annals of the rheumatic diseases.

[24]  Y. Shoenfeld,et al.  Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. , 2010, Autoimmunity reviews.

[25]  C. Denton,et al.  Autoantibodies as predictive tools in systemic sclerosis , 2010, Nature Reviews Rheumatology.

[26]  B. Cai,et al.  MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of systemic lupus erythematosus. , 2009, Rheumatology.

[27]  M. Mahler,et al.  Standardisation of myositis-specific antibodies: where are we today? , 2019, Annals of the Rheumatic Diseases.

[28]  D. Solomon,et al.  Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta‐Analysis , 2018, Arthritis care & research.

[29]  Azin Mirzazadeh,et al.  Pathogenic and protective roles of cytokines in pemphigus: A systematic review. , 2020, Cytokine.

[30]  E. Juengst,et al.  Why Does the Shift from "Personalized Medicine" to "Precision Health" and "Wellness Genomics" Matter? , 2018, AMA journal of ethics.

[31]  L. Gossec,et al.  Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in Rheumatology , 2019, Arthritis care & research.

[32]  F. Ingegnoli,et al.  COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.

[33]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[34]  V. Fineschi Editorial: Personalized Medicine: A Positional Point of View about Precision Medicine and Clarity for Ethics of Public Health. , 2017, Current Pharmaceutical Biotechnology.

[35]  Laura C. Cappelli,et al.  Rheumatic immune-related adverse events from cancer immunotherapy , 2018, Nature Reviews Rheumatology.

[36]  Belchin Kostov,et al.  Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. , 2015, Autoimmunity reviews.

[37]  C. Ding Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases , 2008, Expert opinion on biological therapy.

[38]  C. Bombardier,et al.  Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. , 2016, Rheumatology.

[39]  D. Pisetsky Evolving story of autoantibodies in systemic lupus erythematosus. , 2019, Journal of autoimmunity.

[40]  J. Norris,et al.  A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. , 2016, JCI insight.

[41]  G. Gulati,et al.  Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus , 2018, Pediatric Nephrology.

[42]  G. Kaplan,et al.  Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment , 2020, PloS one.

[43]  Yu Song,et al.  Wearable and Implantable Electronics: Moving toward Precision Therapy. , 2019, ACS nano.

[44]  D. Kansagara,et al.  Implementation Processes and Pay for Performance in Healthcare: A Systematic Review , 2016, Journal of general internal medicine.

[45]  Alfio V Parisi,et al.  A review on the ability of smartphones to detect ultraviolet (UV) radiation and their potential to be used in UV research and for public education purposes. , 2019, The Science of the total environment.

[46]  U. Müller-Ladner,et al.  Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey , 2019, Arthritis Research & Therapy.

[47]  L. Ou,et al.  Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous , 2019, Pediatric Rheumatology.

[48]  Y. Shoenfeld Primary biliary cirrhosis and autoimmune rheumatic diseases: prediction and prevention. , 1992, Israel journal of medical sciences.

[49]  M. Rosenthal,et al.  Beyond pay for performance--emerging models of provider-payment reform. , 2008, The New England journal of medicine.

[50]  D. Bessis,et al.  Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis. , 2019, Acta dermato-venereologica.

[51]  S. Bombardieri,et al.  COVID-19: the new challenge for rheumatologists. , 2020, Clinical and experimental rheumatology.

[52]  Eric J Topol,et al.  High-performance medicine: the convergence of human and artificial intelligence , 2019, Nature Medicine.

[53]  E. Matteson,et al.  Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity. , 2019, Mayo Clinic proceedings.

[54]  K. Latinis,et al.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[55]  V. Pascual,et al.  Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus , 2020, Nature Medicine.

[56]  G. Barturen,et al.  SLE redefined on the basis of molecular pathways. , 2017, Best practice & research. Clinical rheumatology.

[57]  D. Hilbert,et al.  The discovery and development of belimumab: the anti-BLyS–lupus connection , 2012, Nature Biotechnology.

[58]  W. Marlicz,et al.  “Dr. Google, I am in Pain”—Global Internet Searches Associated with Pain: A Retrospective Analysis of Google Trends Data , 2020, International journal of environmental research and public health.

[59]  Carl Shen,et al.  Accuracy of a Popular Online Symptom Checker for Ophthalmic Diagnoses. , 2019, JAMA ophthalmology.

[60]  O. Hamdy,et al.  Patient-Driven Diabetes Care of the Future in the Technology Era. , 2019, Cell metabolism.

[61]  I. Bruce,et al.  Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach , 2018, Arthritis care & research.

[62]  A. Aussy,et al.  Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer , 2017, Front. Immunol..

[63]  Manolis Tsiknakis,et al.  Deep learning opens new horizons in personalized medicine , 2019, Biomedical reports.

[64]  D. Furst,et al.  Annual Medical Costs and Healthcare Resource Use in Patients with Systemic Sclerosis in an Insured Population , 2012, The Journal of Rheumatology.

[65]  J. Harley,et al.  Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus , 2007, Lupus.

[66]  S. Kalra,et al.  Artificial Intelligence/Machine Learning in Diabetes Care , 2019, Indian journal of endocrinology and metabolism.

[67]  H. Brunner,et al.  THU0547 Real-world effectiveness of early aggressive treatment with biological disease-modifying antirheumatic drugs for the treatment of newly diagnosed polyarticular form of juvenile idiopathic arthritis , 2018, THURSDAY, 14 JUNE 2018.

[68]  Francisco Herrera,et al.  Deep Learning in Omics Data Analysis and Precision Medicine , 2019, Computational Biology.

[69]  Andrea Zaccaria,et al.  Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis , 2020, PloS one.

[70]  Y. Shoenfeld,et al.  Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. , 2015, Autoimmunity reviews.

[71]  M. Dougados,et al.  EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases , 2019, RMD Open.

[72]  Brian W Wu,et al.  Redefining Health: The Evolution of Health Ideas from Antiquity to the Era of Value-Based Care , 2017, Cureus.

[73]  M. Buch,et al.  The 'therapeutic window' and treating to target in rheumatoid arthritis. , 2013, Clinical medicine.

[74]  P. Badrinath,et al.  Defining Health in the Era of Value-based Care: Lessons from England of Relevance to Other Health Systems , 2017, Cureus.

[75]  B. Fu,et al.  Identification of circular RNAs hsa_circ_0044235 and hsa_circ_0068367 as novel biomarkers for systemic lupus erythematosus , 2019, International journal of molecular medicine.

[76]  Ami A. Shah,et al.  Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. , 2017, Clinical and experimental rheumatology.

[77]  L. Trouw,et al.  Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. , 2012, Autoimmunity reviews.

[78]  E. Topol,et al.  The Pathway to Patient Data Ownership and Better Health. , 2017, JAMA.

[79]  Y. Shoenfeld,et al.  Immunomodulation for treatment and prevention of atherosclerosis. , 2002, Autoimmunity reviews.

[80]  M. Ando,et al.  Effectiveness of Lifestyle Intervention Using the Internet of Things System for Individuals with Early Type 2 Diabetes Mellitus , 2020, Internal medicine.

[81]  P. Emery,et al.  A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals , 2016, Current opinion in rheumatology.

[82]  E. Topol Digital medicine: empowering both patients and clinicians , 2016, The Lancet.

[83]  J. Schoones,et al.  What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review , 2013, Annals of the rheumatic diseases.

[84]  Shun-Chiao Chang,et al.  Influence of Alcohol Consumption on the Risk of Systemic Lupus Erythematosus Among Women in the Nurses’ Health Study Cohorts , 2017, Arthritis care & research.

[85]  N. Bansback,et al.  Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review , 2019, The Journal of Rheumatology.

[86]  Takanori Hasegawa,et al.  The Potential Possibility of Symptom Checker , 2017, International journal of health policy and management.

[87]  J. Rosenbloom,et al.  Existing and novel biomarkers for precision medicine in systemic sclerosis , 2018, Nature Reviews Rheumatology.

[88]  C. Allaart,et al.  Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example , 2017, Arthritis & rheumatology.

[89]  R. Green,et al.  Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. , 2014, Contemporary clinical trials.

[90]  John M. Marzo,et al.  How Accurate Are Patients at Diagnosing the Cause of Their Knee Pain With the Help of a Web-based Symptom Checker? , 2016, Orthopaedic journal of sports medicine.

[91]  T. Huizinga,et al.  The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis , 2015, Arthritis Research & Therapy.

[92]  Kibum Kim,et al.  The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. , 2018, Personalized medicine.

[93]  Yangqiu Li,et al.  Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology , 2019, Cancer biology & medicine.

[94]  A. Cope Considerations for Optimal Trial Design for Rheumatoid Arthritis Prevention Studies. , 2019, Clinical therapeutics.

[95]  Xu Chen,et al.  Potential protein biomarkers for systemic lupus erythematosus determined by bioinformatics analysis , 2019, Comput. Biol. Chem..

[96]  J. Sparks,et al.  Mobile Apps for Individuals With Rheumatoid Arthritis: A Systematic Review , 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[97]  Sharareh R. Niakan Kalhori,et al.  Artificial Intelligence Applications in Type 2 Diabetes Mellitus Care: Focus on Machine Learning Methods , 2019, Healthcare informatics research.

[98]  G. T. Sharrer Personalized Medicine: Ethical Aspects. , 2017, Methods in molecular biology.

[99]  A. Cope,et al.  Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus. , 2018, Journal of autoimmunity.

[100]  R. Moscicki,et al.  Drug‐Development Challenges for Small Biopharmaceutical Companies , 2017, The New England journal of medicine.

[101]  E. Karlson,et al.  Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody–Positive Patients Without Rheumatoid Arthritis , 2019, Arthritis care & research.

[102]  J. Norris,et al.  Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment , 2015, Rheumatology.

[103]  Rostyslav V Bubnov,et al.  Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine? , 2017, EPMA Journal.

[104]  S. Kauffman,et al.  Study design and the drug development process. , 2014, JAMA.

[105]  M. Freedman,et al.  Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment , 2020, Multiple sclerosis.

[106]  E. Cummins,et al.  Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis , 2013, BMJ Open.

[107]  M. Fritzler,et al.  Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care , 2016, Lupus.

[108]  A. Clarke,et al.  Socioeconomic consequences of systemic lupus erythematosus , 2017, Current opinion in rheumatology.

[109]  Benjamin Marshall Davies,et al.  A Novel Insight Into the Challenges of Diagnosing Degenerative Cervical Myelopathy Using Web-Based Symptom Checkers , 2019, Journal of medical Internet research.

[110]  D. Marshall,et al.  Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives , 2020, Arthritis care & research.

[111]  May Y. Choi,et al.  The Utilization of Autoantibodies in Approaches to Precision Health , 2018, Front. Immunol..

[112]  L. Trouw,et al.  Rheumatoid arthritis: Autoantibody testing to predict response to therapy in RA , 2016, Nature Reviews Rheumatology.

[113]  N. Rose Prediction and Prevention of Autoimmune Disease , 2007, Annals of the New York Academy of Sciences.

[114]  William G. Dixon,et al.  Using technology to support clinical care and research in rheumatoid arthritis , 2018, Current opinion in rheumatology.

[115]  A. Filer,et al.  The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? , 2015, Annals of the rheumatic diseases.

[116]  J. Seidman,et al.  Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. , 2019, Circulation research.

[117]  K. Deane Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention , 2018, Current Rheumatology Reports.

[118]  Brenden Rossin,et al.  Augmented versus artificial intelligence for stratification of patients with myositis , 2019, Annals of the Rheumatic Diseases.

[119]  M. Guiguet,et al.  Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies , 2018, JAMA neurology.

[120]  W. Dixon,et al.  2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis , 2018, Annals of the rheumatic diseases.

[121]  I. Bruce,et al.  Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach , 2020, Arthritis care & research.

[122]  E. Smolewska,et al.  Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience , 2018, Reumatologia.

[123]  T. Niewold,et al.  Lessons from precision medicine in rheumatology , 2020, Multiple sclerosis.

[124]  G. Simons,et al.  Are online symptoms checkers useful for patients with inflammatory arthritis? , 2016, BMC Musculoskeletal Disorders.

[125]  E. Smolewska,et al.  In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis—Are We Getting Closer to Personalised Medicine? , 2017, Current Rheumatology Reports.

[126]  D. Cortese,et al.  Pay-for-performance or pay for value? , 2007, Mayo Clinic proceedings.

[127]  E. Karlson,et al.  Impact and Timing of Smoking Cessation on Reducing Risk of Rheumatoid Arthritis Among Women in the Nurses’ Health Studies , 2019, Arthritis care & research.

[128]  S. Nagpal,et al.  Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics , 2020, Contemporary clinical trials communications.

[129]  V. Ronca,et al.  Prognostic models in primary biliary cholangitis. , 2018, Journal of autoimmunity.

[130]  G. Burmester Rheumatology 4.0: big data, wearables and diagnosis by computer , 2018, Annals of the rheumatic diseases.

[131]  V. Ronca,et al.  Precision medicine in primary biliary cholangitis , 2019, Journal of digestive diseases.

[132]  Y. Shoenfeld,et al.  Readability of Wikipedia Pages on Autoimmune Disorders: Systematic Quantitative Assessment , 2017, Journal of medical Internet research.

[133]  L. Arnaud,et al.  Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. , 2019, Joint, bone, spine : revue du rhumatisme.

[134]  Jennifer P D'Auria,et al.  Googling for health information. , 2012, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[135]  N. Rose Prediction and Prevention of Autoimmune Disease in the 21st Century: A Review and Preview. , 2016, American journal of epidemiology.

[136]  John B. Watkins,et al.  Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[137]  N. Olsen,et al.  Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial , 2018, Trials.

[138]  Zhi Geng,et al.  Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine , 2019, Public Health Genomics.

[139]  Jeffrey Dean,et al.  Machine Learning in Medicine , 2019, The New England journal of medicine.

[140]  L. Hood,et al.  A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. , 2012, New biotechnology.

[141]  P. V. van Riel,et al.  Patient Self-Management and Tracking: A European Experience. , 2019, Rheumatic diseases clinics of North America.

[142]  A. Silman,et al.  Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study , 2018, Annals of the rheumatic diseases.

[143]  J. Ingelfinger,et al.  Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention. , 2019, The New England journal of medicine.

[144]  Ritesh G. Menezes,et al.  Personalized Medicine in a New Genomic Era: Ethical and Legal Aspects , 2017, Sci. Eng. Ethics.

[145]  Y. Allenbach,et al.  Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. , 2019, Autoimmunity reviews.

[146]  J. Pollard,et al.  Conduction block in immune‐mediated neuropathy: paranodopathy versus axonopathy , 2019, European journal of neurology.

[147]  E. Topol,et al.  Disruptive Innovation in Laboratory Medicine. , 2015, Clinical Chemistry.

[148]  J. Norris,et al.  Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE , 2019, Lupus.

[149]  E. Topol,et al.  Patient Data Ownership-Reply. , 2018, Journal of the American Medical Association (JAMA).

[150]  V. Pascual,et al.  Unique Sjögren's syndrome patient subsets defined by molecular features. , 2020, Rheumatology.

[151]  Xiao Li,et al.  B Cell-Related Circulating MicroRNAs With the Potential Value of Biomarkers in the Differential Diagnosis, and Distinguishment Between the Disease Activity and Lupus Nephritis for Systemic Lupus Erythematosus , 2018, Front. Immunol..

[152]  A. Tincani,et al.  Autoantibodies’ titre modulation by anti-BlyS treatment in systemic lupus erythematosus , 2019, Lupus.

[153]  C. Ruiz,et al.  Vitamin D and autoimmune diseases. , 2019, Life sciences.

[154]  R. Green,et al.  Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial , 2018, Arthritis care & research.

[155]  D. Tang,et al.  Advances in applying of multi-omics approaches in the research of systemic lupus erythematosus , 2020, International reviews of immunology.

[156]  I. Nishino,et al.  Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. , 2020, Autoimmunity reviews.

[157]  L. Klareskog,et al.  The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting , 2016, Nature Reviews Immunology.

[158]  John Nelson,et al.  Activity level classification algorithm using SHIMMER™ wearable sensors for individuals with rheumatoid arthritis , 2011, 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[159]  Hailiang Liu,et al.  Novel biomarkers containing citrullinated peptides for diagnosis of systemic lupus erythematosus using protein microarrays. , 2019, Clinical and experimental rheumatology.

[160]  P. Roux‐Lombard,et al.  Value of Biomarkers in the Prevention of Rheumatoid Arthritis , 2017, Clinical pharmacology and therapeutics.

[161]  Marcus Woo,et al.  An AI boost for clinical trials , 2019, Nature.

[162]  E. Reis,et al.  Evaluation of potential biomarkers for the diagnosis and monitoring of Systemic Lupus Erythematosus using the Cytometric Beads Array (CBA). , 2019, Clinica chimica acta; international journal of clinical chemistry.

[163]  T. Huizinga,et al.  Triple Positivity for Anti–Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti–Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis , 2018, Arthritis & rheumatology.

[164]  A. Elliot,et al.  Internet-based remote health self-checker symptom data as an adjuvant to a national syndromic surveillance system , 2015, Epidemiology and Infection.

[165]  M. Fritzler,et al.  Detection of myositis-specific antibodies: additional notes , 2018, Annals of the rheumatic diseases.

[166]  J. Norris,et al.  Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus , 2018, Lupus.

[167]  K. Raza,et al.  Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives , 2019, RMD Open.

[168]  Robert N. Anderson,et al.  Potentially Preventable Deaths from the Five Leading Causes of Death — United States, 2008–2010 , 2014, MMWR. Morbidity and mortality weekly report.

[169]  C. Cobelli,et al.  Continuous Glucose Monitoring Linked to an Artificial Intelligence Risk Index: Early Footprints of Intraventricular Hemorrhage in Preterm Neonates. , 2019, Diabetes technology & therapeutics.

[170]  M. Fritzler Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. , 2016, Autoimmunity reviews.

[171]  M. Petri,et al.  Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response , 2012, Annals of the rheumatic diseases.

[172]  P. V. van Diest,et al.  Ethical considerations for modern molecular pathology , 2018, The Journal of pathology.

[173]  C. Langefeld,et al.  Association of SLCO1B1 *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients , 2019, ACR open rheumatology.

[174]  Eric J Topol,et al.  Information and Artificial Intelligence. , 2018, Journal of the American College of Radiology : JACR.

[175]  S. Jimenez,et al.  Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis , 2018, Rheumatology.

[176]  J. Krischer,et al.  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. , 2019, The New England journal of medicine.

[177]  Jessilyn Dunn,et al.  Wearables and the medical revolution. , 2018, Personalized medicine.

[178]  Md. Asiful Islam,et al.  Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis. , 2020, Current gene therapy.

[179]  S. Steinhubl,et al.  Advanced and Accurate Mobile Health Tracking Devices Record New Cardiac Vital Signs , 2018, Hypertension.

[180]  G. Mells,et al.  Individualizing Care: Management Beyond Medical Therapy. , 2018, Clinics in liver disease.

[181]  Claudia Douglas,et al.  The HackensackUMC Value-Based Care Model: Building Essentials for Value-Based Purchasing , 2016, Nursing administration quarterly.

[182]  Michael A. Smith,et al.  SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus , 2019, Scientific Reports.

[183]  D. Hayes,et al.  A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells , 2019, Nature Communications.

[184]  J. Manning,et al.  Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study , 2018, Scandinavian journal of rheumatology.

[185]  J. Vallat,et al.  Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[186]  G. Iskrov,et al.  Social/economic costs and health-related quality of life in patients with scleroderma in Europe , 2016, The European Journal of Health Economics.

[187]  G. Espinosa,et al.  Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting , 2019, Scandinavian journal of rheumatology.

[188]  Ami A. Shah,et al.  Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer , 2018, Annals of the rheumatic diseases.

[189]  F. Berenbaum,et al.  Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review , 2019, JMIR mHealth and uHealth.

[190]  A. Zwinderman,et al.  Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study , 2018, Annals of the rheumatic diseases.

[191]  Nathan Foulquier,et al.  How Health Information Technologies and Artificial Intelligence May Help Rheumatologists in Routine Practice , 2019, Rheumatology and Therapy.

[192]  J. Norris,et al.  Genetic and environmental risk factors for rheumatoid arthritis. , 2017, Best practice & research. Clinical rheumatology.

[193]  C. Denton,et al.  Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis , 2020, Arthritis & rheumatology.

[194]  W. Alkema,et al.  Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels. , 2020, Autoimmunity reviews.

[195]  Ami A. Shah,et al.  More Than Skin Deep: Bringing Precision Medicine to Systemic Sclerosis , 2020, Arthritis & rheumatology.

[196]  C. Gidengil,et al.  Evaluation of symptom checkers for self diagnosis and triage: audit study , 2015, BMJ : British Medical Journal.

[197]  W. Riley,et al.  Precision Public Health for the Era of Precision Medicine. , 2016, American journal of preventive medicine.

[198]  G. Hazlewood Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments. , 2018, Rheumatic diseases clinics of North America.

[199]  S. Doyle-Lindrud,et al.  Watson will see you now: a supercomputer to help clinicians make informed treatment decisions. , 2015, Clinical journal of oncology nursing.

[200]  G. Gibson,et al.  PART of the WHOLE: A Case Study in Wellness-Oriented Personalized Medicine , 2015, The Yale journal of biology and medicine.

[201]  Anjuli Kannan,et al.  Automatically Charting Symptoms From Patient-Physician Conversations Using Machine Learning. , 2019, JAMA internal medicine.

[202]  Neil Mehta,et al.  Policy Implications of Artificial Intelligence and Machine Learning in Diabetes Management , 2020, Current Diabetes Reports.

[203]  Eric J. Topol,et al.  The big medical data miss: challenges in establishing an open medical resource , 2015, Nature Reviews Genetics.

[204]  A. Finckh,et al.  Is the prevention of rheumatoid arthritis possible? , 2020, Clinical Rheumatology.

[205]  B. Fu,et al.  Circular RNAs hsa_circ_0000479 in peripheral blood mononuclear cells as novel biomarkers for systemic lupus erythematosus , 2020, Autoimmunity.

[206]  E. Pezzarini,et al.  Oxidative stress, inflammation and disease activity biomarkers in lupus nephropathy , 2020, Lupus.

[207]  P. Emery,et al.  Prevention and cure: The major unmet needs in the management of rheumatoid arthritis. , 2019, Journal of autoimmunity.

[208]  P. Lipsky,et al.  New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti‐DNA , 2016, Arthritis & rheumatology.

[209]  P. Sfikakis,et al.  The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. , 2020, Autoimmunity reviews.

[210]  N. Olsen,et al.  Emerging technologies in autoantibody testing for rheumatic diseases , 2017, Arthritis Research & Therapy.